# Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients

> **NCT04917484** · PHASE2 · RECRUITING · sponsor: **Tine Gregersen, MD** · enrollment: 100 (estimated)

## Conditions studied

- Neuroendocrine Neoplasm

## Interventions

- **DRUG:** Lu-177-DOTA-Octreotide

## Key facts

- **NCT ID:** NCT04917484
- **Lead sponsor:** Tine Gregersen, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-02-01
- **Primary completion:** 2025-12
- **Final completion:** 2026-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04917484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04917484, "Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04917484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*